Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.34 |
| ▸ | ADH1A | P07327 | 4/20 | 0.32 |
| ▸ | ADH1C | P00326 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449085 | 0.97 | LTA4H (0.38) | LTA4HSLC6A2SLC6A4SLC6A3ALOX5 | |
| SCHEMBL13082953 | 0.83 | ADH1A (0.42) | LTA4HSLC6A2SLC6A4SLC6A3ALOX5 | |
| SCHEMBL18602764 | 0.81 | ADH1C (0.35) | LTA4HALOX5ADH1AADH1C | |
| SCHEMBL13683429 | 0.79 | CYP1A2 (0.33) | LTA4HSLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL9289339 | 0.79 | ADH1A (0.46) | LTA4HADH1AADH1C | |
| SCHEMBL9283447 | 0.78 | CYP1A2 (0.35) | LTA4HSLC6A2SLC6A4SLC6A3ADH1A | |
| SCHEMBL9290239 | 0.78 | ADH1A (0.41) | ADH1AADH1C | |
| SCHEMBL12448946 | 0.76 | — | — | |
| SCHEMBL26773083 | 0.76 | — | — | |
| SCHEMBL20803869 | 0.76 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | LTA4H 2296/4885SLC6A2 310/4885SLC6A4 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.